The Significance of the Ipilimumab/Nivolumab Findings in Melanoma

Video

Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses the significance of the ipilimumab/nivolumab findings from the CheckMate-069 trial for melanoma.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
Related Content